More recently, in a study based on long-term follow-up data of RTOG trial 9402, IDH mutations were identified as a predictive biomarker that conferred survival benefit to patients with WHO III anaplastic oligodendrogliomas receiving PCV chemotherapy, but not in those without PCV chemotherapy [15]. This evidence concerns the gene IDH2 and anaplastic oligodendroglioma.